Mostrar el registro sencillo del ítem

Off‐label Use of Tocilizumab in Patients with SARS‐CoV‐2 Infection

dc.contributor.authorDi Giambenedetto, Simona, et al.
dc.date.accessioned2020-04-30T01:08:28Z
dc.date.available2020-04-30T01:08:28Z
dc.date.issued2020-04-16
dc.identifier.urihttps://doi.org/10.1002/jmv.25897en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/1247
dc.description.abstractThe spread of the novel‐Coronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized anti‐human inteleukine‐6 receptor antibody tocilizumab seems a promising strategy for these patients.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirusen_US
dc.subjectInfectious Diseasesen_US
dc.titleOff‐label Use of Tocilizumab in Patients with SARS‐CoV‐2 Infectionen_US
eihealth.countryOthersen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalJournal of Medical Virologyen_US


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem